Arrowhead Research Corp: Finding Cure for Obesity and the HBV Infection

One of the biopharmaceutical companies that have focused its resources on programs and therapeutics in oncology is Arrowhead Research Corp. The company also has several clinical programs that are already in the pipeline to combat obesity and chronic hepatitis B.

The novel therapeutics that are being studied and developed by the business are based on RNAi therapeutics. There are two product candidates of the company that are currently on Phase 1 clinical trial. The ARC-520 is their flagship medication that is intended to combat the HBV infection, their Adipotide is created to address obesity and other metabolic disorders. The RNAi interference mechanism that is the foundation of their products is created to efficiently silence disease-causing genes while sparing off-target tissues.

Headquartered in Pasadena, California, Arrowhead Research has been around since 2003. Currently, they have two platform technologies that serve as a broad base for their product development: Homing Peptides and Dynamic Polyconjugates.